The price of POZEN Inc.(Nasdaq:POZN) stock surged on Tuesday's market activity after the company reported that AstraZeneca AB and Horizon Pharma USA, Inc. have entered into an agreement for Horizon to acquire the U.S. rights for VIMOVO.
POZN entered into a collaboration agreement with AstraZeneca on August 1, 2006 for the co-development and commercialization of VIMOVO.
According to the company and under the terms of the agreement, POZN will continue to receive a 10% royalty on Net Sales of products sold in the U.S., with guaranteed annual minimum royalty payments of $5 million in 2014, and $7.5 million each year thereafter, provided that the patents owned by POZN which cover VIMOVO are in effect and no generic forms of VIMOVO are on the market.
Shares of Intellipharmaceutics International Inc.(Nasdaq:IPCI) skyrocketed on Tuesday's trading session after the company reported that the FDA has granted final approval of the Company's dexmethylphenidate hydrochloride extended-release capsules for the 15 and 30 mg strengths
IPCI's dexmethylphenidate hydrochloride extended-release capsules are the generic version of Focalin XR(R), a drug-used in the treatment of attention deficit hyperactivity disorder, marketed by Novartis Pharmaceuticals Corporation.
According to Source Healthcare Analytics, sales for the 12 months ended October 2013 of Focalin XR(R) 15 and 30 mg, respectively, in the U.S. were approximately $136 million and $69 million (TRx MBS Dollars, which represents projected new and refilled prescriptions representing a standardized dollar metric based on manufacturer's published catalog or list prices to wholesalers, and does not represent actual transaction prices and does not include prompt pay or other discounts, rebates or reductions in price).
According to Nektar Therapeutics (Nasdaq:NKTR), its partner AstraZeneca reported that the FDA has accepted the New Drug-Application (NDA) for naloxegol, an investigational peripherally-acting mu-opioid receptor antagonist (PAMORA), which has been studied in opioid-induced constipation (OIC) in adult patients with chronic non-cancer pain, the most common side effect caused by chronic administration of prescription opioid-pain medicines.
Naloxegol, developed using NKTR's oral small molecule polymer conjugate technology, has the potential to be the first once-daily oral PAMORA for patients with OIC in the U.S.
Naloxegol is part of the exclusive worldwide license agreement announced on 21 September 2009, between AstraZeneca and NKTR. Under the terms of the amended license agreement, AstraZeneca will make a $70 million milestone payment to NKTR within five business days of acceptance of the NDA by the FDA.
U.S. companies and government agencies will purchase $559 billion via the web in 2013, Forrester Research Inc. predicted in its first estimate of the b2b e-commerce market released last year. The study gave no percentage growth figures.
Crown Equity Holdings Inc.(CRWE) is looking to deliver value for its stockholders in both the near and long term, and to improve the potential future growth for the company, CRWE is targeting the multi-billion dollar online b2b market.
Strategic plans are being developed for CRWE’s iB2B Global project.
Full article at http://pennyomega.com/28478/stock-alerts/inte...